| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/05/2005 | EP1493443A1 Use of pyridoxal phosphate for the treatment of diabetes and related complications |
| 01/05/2005 | EP1493433A1 Porous particles loaded with cosmetical or pharmaceutical active agents |
| 01/05/2005 | EP1493034A2 Method for diagnosing inflammatory diseases and infections by the determination of lasp-1 immunoreactivity |
| 01/05/2005 | EP1493033A2 Sc6 for diagnosis of hypoxia related conditions |
| 01/05/2005 | EP1493028A2 Phage displayed pdz domain ligands |
| 01/05/2005 | EP1492883A2 Diagnostics and therapeutics for diseases associated with neuropeptide ff receptor 2 (npff2) |
| 01/05/2005 | EP1492821A1 Iron dextrin compounds for the treatment of iron deficiency anaemia |
| 01/05/2005 | EP1492817A2 Therapeutic monoclonal anti-tirc7 antibodies for use in immune related and other diseases |
| 01/05/2005 | EP1492784A2 Substituted 2,3-diphenyl pyridines |
| 01/05/2005 | EP1492780A1 5-substituted 1,1-dioxo-[1,2,5]thiazolidine-3-one derivatives as ptpase 1b inhibitors |
| 01/05/2005 | EP1492772A1 Farnesyl protein transferase inhibitors as antitumor agents |
| 01/05/2005 | EP1492595A1 Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist |
| 01/05/2005 | EP1492577A1 Film-forming compositions for protecting skin from body fluids and articles made therefrom |
| 01/05/2005 | EP1492568A1 Cancer treatment method comprising administration of an erb-family inhibitor and a raf and/or ras inhibitor |
| 01/05/2005 | EP1492567A1 Formulations and methods of using nitric oxide mimetics in cancer treatment |
| 01/05/2005 | EP1492566A2 Binding agents and their use in targeting tumor cells |
| 01/05/2005 | EP1492563A2 Compositions and methods for the diagnosis and treatment of herpes simplex virus infection |
| 01/05/2005 | EP1492560A2 Use of interleukin-19 to treat cervical cancer |
| 01/05/2005 | EP1492555A2 Compositions and methods for modulation of effects on phagocyte and lymphoid cell population |
| 01/05/2005 | EP1492552A2 Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1) |
| 01/05/2005 | EP1492549A1 Compositions and methods for augmenting kidney function |
| 01/05/2005 | EP1492548A1 Composition for the topical treatment of vulvovaginitis and mycoses |
| 01/05/2005 | EP1492544A1 Pharmaceutical compositions containing water-soluble prodrugs of propofol and methods of administering same |
| 01/05/2005 | EP1492541A1 Pharmaceutical compositions comprising a 11-beta hydroxysteroid dehydrogenase inhibitor and a diuretic agent |
| 01/05/2005 | EP1492525A2 Use of inhibitors of proline endopeptidase to modulate inositol (1,4,5) triphosphate concentration dependent on intracellular signal cascades |
| 01/05/2005 | EP1492519A1 Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators |
| 01/05/2005 | EP1492518A2 Tuberculosis treatment using pleuromutilin derivatives |
| 01/05/2005 | EP1492516A2 Use of mob-5 in pain |
| 01/05/2005 | EP1492512A1 Method for systemic drug delivery through the nail |
| 01/05/2005 | EP1492508A1 Controlled release dosage forms |
| 01/05/2005 | EP1492487A2 Mitotic kinesin inhibitors |
| 01/05/2005 | EP1492415A2 Method of improving absorption of vitamin e by a pet animal |
| 01/05/2005 | EP1492414A2 Method and dietary composition for improving fat digestibility |
| 01/05/2005 | EP1492413A2 Method and dietary composition for improving lipid digestibility |
| 01/05/2005 | EP1397138B1 ACTIVE INGREDIENT COMBINATION (e.g. galanthamine or desoxypeganine with acamprosate or Memantine) FOR TREATING A DEPENDENCE ON ADDICTIVE SUBSTANCES OR NARCOTICS |
| 01/05/2005 | EP1253947A4 Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen |
| 01/05/2005 | EP1248630B9 Use of a dermatological composition containing oligosaccharides for the treatment of skin diseases |
| 01/05/2005 | EP1227814B1 Hormonal composition based on nomegestrol acetate and an oestrogen and use thereof |
| 01/05/2005 | EP1169035B1 Anti-tumor synergetic composition |
| 01/05/2005 | EP0957914B1 Formulation of 5-ht agonists |
| 01/05/2005 | DE202004015931U1 Omega-3-Fettsäuren und Omega-6-Fettsäuren enthaltende Zusammensetzung Omega-3 fatty acids and omega-6 fatty acids containing composition |
| 01/05/2005 | DE10329839A1 Use of artificial nutrition solutions to treat skin diseases, especially psoriasis, neurodermatitis, acne, dermatoses or eczema |
| 01/05/2005 | DE10326821A1 Pharmazeutische Kombinationspräparate zur Krebstherapie Pharmaceutical combination preparations for cancer therapy |
| 01/05/2005 | DE10325813A1 Prophylaxe und/oder Therapie bei der portalen Hypertonie Prophylaxis and / or therapy of portal hypertension in |
| 01/05/2005 | CN1561393A Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma |
| 01/05/2005 | CN1561387A Probiotic bifidobacterium strains |
| 01/05/2005 | CN1561344A Angiogenesis-inhibitory tripeptides, compositions and their methods of use |
| 01/05/2005 | CN1561246A Compositions of cyclooxygenase-2 selective inhibitors and radiation for inhibition or prevention of cardiovascular disease |
| 01/05/2005 | CN1561225A Modulation of leukocyte-endothelial interactions following ischemia |
| 01/05/2005 | CN1561220A Method for the treatment of inflammation |
| 01/05/2005 | CN1561219A Pharmaceutical compounds |
| 01/05/2005 | CN1561208A Methods to mobilize progenitor/stem cells |
| 01/05/2005 | CN1561204A Use of COX-2 inhibitors for preventing immunodeficiency |
| 01/05/2005 | CN1561203A Pharmaceutical salts |
| 01/05/2005 | CN1559613A Medicinal invert sugar injection |
| 01/05/2005 | CN1559612A Medicinal mixture for treating digestire system anabrosis |
| 01/05/2005 | CN1559384A Injection temp-sensing type implanting prepns. |
| 01/05/2005 | CN1183250C Virus with specigic reproduction in tumor well and effective expression of tumor angiogenesis nihibitory factor and its construction method |
| 01/05/2005 | CN1182872C Use of (meth) acrylic acid copolymers to increase permeability of mucous membranes |
| 01/05/2005 | CN1182869C Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restemosis |
| 01/05/2005 | CN1182841C New pharmaceutical formulation and preparation process |
| 01/05/2005 | CN1182839C Ascending-dose dosage form |
| 01/04/2005 | US6838559 Such as 2-((6-(((4-(3,4-dimethoxyphenyl)methyl)amino)-7-ethyl-7H-purin-2-yl)amino) -4,5-methyl-N-phenyl-5-thiazole-carboxamide for treatment of lymphocyte mediated diseases such as transplant rejection and graft versus host disease |
| 01/04/2005 | US6838552 Diagnosis and management of infection caused by Chlamydia |
| 01/04/2005 | US6838547 Acryloyl derivatives of distamycin conjugated with glutathione; have antitumor activity and are thus useful in therapy in the treatment of cancer |
| 01/04/2005 | US6838493 Biocompatible with controlled degradation rates |
| 01/04/2005 | US6838480 Composition containing sucrafate and a topical anesthetic for humans and animals and method of use thereof |
| 01/04/2005 | US6838475 For prophylaxis and therapy of one or more symptoms of hepatitis C |
| 01/04/2005 | US6838474 Prodrugs of a class of sulfonamides which are aspartyl protease inhibitors. This invention relates to a novel class of prodrugs of HIV aspartyl protease inhibitors characterized by favorable aqueous solubility, high oral bioavailability and |
| 01/04/2005 | US6838471 Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
| 01/04/2005 | US6838469 Pharmaceutical composition that exhibits reduced side-effects comprising O-(3-piperidino-2-hydroxy-1-propyl)nicotinic acid amidoxime and a pyrimidine derivative with known antitumor activity |
| 01/04/2005 | US6838467 Dosing regimen |
| 01/04/2005 | US6838451 Mixture of glucosamine, linoleic acid and ascorbic acid; bone diosrders, antiarthritic agents, antiinflammatory agents |
| 01/04/2005 | US6838449 Ophthalmic compositions containing galactomannan polymers and borate |
| 01/04/2005 | US6838442 Administering to said subject a jointly effective amount of a glucose reabsorption inhibitor; administering jointly effective amount of an retinoid-X receptor modulator for therapy of diabetes or Syndrome X |
| 01/04/2005 | US6838436 Osteoporosis, bone fractures, oral diseases; administering a protein |
| 01/04/2005 | US6838428 A non-human mammal phenotype, vectors expressing the protein for treating respiratory system disease, viral diseases, purifying SP-D antibodies, enzyme inhibitor of metalloproteinase |
| 01/04/2005 | US6838261 Nucleic acids encoding anti-CD40 proteins and methods of producing recombinant anti-CD40 proteins |
| 01/04/2005 | US6838252 Inhibitors of proteasomal activity for stimulating hair growth |
| 01/04/2005 | US6838249 Identifying transport protein modulator using gabapentin (GBP) as a transfer/fluid flow indicator; anticonvulsant; neuropathic pain |
| 01/04/2005 | US6838084 For connection with major histomcompatability complex molecules |
| 01/04/2005 | CA2301503C Pharmaceutical compositions for oral administration of molecular iodine |
| 01/01/2005 | CA2472846A1 Methods for assessing and treating leukemia |
| 12/30/2004 | US20040268426 P2Y4 receptor transgenic and knockout non-human mammals |
| 12/30/2004 | US20040268423 inhibiting formation of neurofibrillary tangles by reducing formation of a carboxyl-terminal truncated form of apolipoprotein E (apoE) in a neuron in the individual; animal models of Alzheimer's disease (AD); treating AD; drug screening |
| 12/30/2004 | US20040267028 Such as 2-amino-1-(2-chlorophenyl)-5-(4-chlorophenyl)-N-cyclohexyl-1H-pyrrole-3-carboxamide hydrochloride |
| 12/30/2004 | US20040267004 nucleic acid that binds to high mobility group protein-I (HMG-I), and causes presenilin-2 gene exon 5-lacked type aberrant splicing by the association with the HMG-I protein; an inhibitor for inhibiting a binding between protein-nucleic acid caused by aberrant splicing; drug screening; antisense agents |
| 12/30/2004 | US20040266882 Administering chemotherapeutically effective amount of at least one chemotherapeutic agent and a chemosensitizing effective amount of at least one 3-aryloxy-3-phenylpropylamine such as 3-(p-isopropoxyphenoxy)-3-phenylpropylamine methanesulfonate; advantageous in treatment of multidrug resistance cancer |
| 12/30/2004 | US20040266873 1-butane acid derivatives pharmaceutical compositions containing said derivatives and the use thereof |
| 12/30/2004 | US20040266871 Methods for treating alzheimer's disease using quinaldoyl-amine derivatives of oxo-and hydroxy-substituted hydrocarbons |
| 12/30/2004 | US20040266869 Novel medicament compositions based on anticholinesterase drugs and on ciclesonides |
| 12/30/2004 | US20040266864 Possess potent serotonin reuptake inhibitory activity, with minimal inhibitory effects on the reuptake of other known monoamines, e.g., norepinephrine or dopamine; also useful for treating or preventing other CNS disorders, cerebrovascular or vascular dysfunctions, sexual dysfunctiions, eating disorders |
| 12/30/2004 | US20040266861 Administering a therapeutically effective amount of a compound which is a cannabinoid receptor agonist, a pharmaceutically acceptable salt of the compound, an isomer of the compound, or a pharmaceutically acceptable salt of the isomer |
| 12/30/2004 | US20040266836 Salt of acidic AT1-receptor antagonist and basic cardiovascular ingredient; potentiation or synergism; reduction of side effects |
| 12/30/2004 | US20040266834 Reducing incidence of multidrug resistance; increasing toxicity and efficacy |
| 12/30/2004 | US20040266830 Insulin sensitivity enhancer and second antidiabetic of different mechanism; suppressing hyperglycemia |
| 12/30/2004 | US20040266828 Gastrointestinal disorders; facilitating healing and decreasing recurrence of ulcers; low dosage, reduced side effects |
| 12/30/2004 | US20040266816 Potent and long lasting antimuscarinic agents; respiratory, urological or gastrointestinal disorders |
| 12/30/2004 | US20040266815 Alzheimer's disease, bipolar disorder, diabetes, dementia, stroke, schizophrenia, depression, hair loss, cancer |
| 12/30/2004 | US20040266806 Autoclaved methylnaltrexone preparation having reduced level of degradation products; storage stability; kits |